Advanced Search

Journal of Traditional Chinese Medicine >

2026 , Vol. 46 >Issue 2: 490 - 500

DOI: https://doi.org/10.19852/j.cnki.jtcm.2026.02.020

Original Articles

Candidate biomarker identification for blood stasis syndrome among coronary artery disease patients using the Olink proteomics platform

  • LI Hongzheng ,
  • LIN Guosheng ,
  • PENG Yuxuan ,
  • Churov Alexey Viktorovich ,
  • YANG Wenwen ,
  • WANG Jie ,
  • LU Jieming ,
  • LIAO Feifei ,
  • YU Ruotong ,
  • WEI Yue ,
  • ZHAO Zhiru ,
  • LU Aimei ,
  • LI Peng ,
  • SHEN Aling ,
  • LONG Linzi ,
  • QU Hua ,
  • FU Changgeng
Expand
  • 1 National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
    2 Postdoctoral Research Center, Guang’an Men Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
    3 Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China
    4 Institute of General Pathology and Pathophysiology, Pirogov Russian National Research Medical University, Moscow 125315, Russia
    5 Department of Cardiology, Shaanxi Provincial Hospital of Chinese Medicine, Xi’an 710003, China
    6 Academy of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China
    7 Department of Cardiology I, TCM Hospital Affiliated to Xinjiang Medical University, Urumqi 830000, China
Prof. FU Changgeng, National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China. fucgbs@163.com;
Dr. LONG Linzi, National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China. qixiang830803@163.com; Telephone: +86-15101038490

Received date: 2025-01-15

  Accepted date: 2025-07-02

  Online published: 2026-04-04

Supported by

Formulation of International Diagnostic Criteria for Blood Stasis Syndrome in Coronary Heart Disease and Screening of Specific Protein Biomarkers(CMC2022010);Screening of Inflammatory Biomarkers and Analysis of Perivascular Adipose Tissue Characteristics in Patients with Blood Stasis Syndrome due to Coronary Heart Disease(GWJJMB202510021048);Comprehensive Investigation into Diagnostic Criteria and a Risk Prediction Model for Coronary Heart Disease with "Dryness-Blood Stasis Complex" Syndrome in Xinjiang(2022E02114)

Fold

Abstract

OBJECTIVE: To identify candidate biomarkers of blood stasis syndrome (BSS) associated with coronary artery disease (CAD) and explore the underlying inflammatory mechanisms.

Methods: Using the Olink Target 96 Inflammation panel, we identified plasma proteins in a group of 88 patients comprised of healthy controls (HCs), those with CAD and BSS (CAD-BSS), those with CAD without BSS (CAD-non-BSS), and those with BSS without CAD (non-CAD-BSS) (n = 22 in each group). Protein molecules that were specifically expressed in CAD or BSS were identified by differential expression analyses. Subsequently, potential protein biomarkers were identified using least absolute shrinkage and selection operator regression to enable CAD and BSS differentiation. The potential functional mechanisms of identified proteins were then determined by Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analyses.

RESULTS: Patients with CAD had 31/92 upregulated and 4/92 downregulated proteins compared with those without. Chemokine (C-C motif) ligand 11 (CCL11), CUB domain-containing protein 1, hepatocyte growth factor, sirtuin 2 (SIRT2), eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), CCL25, and tumor necrosis factor (TNF) showed the strongest upregulation (all P <0.0001). Patients with BSS had 8/92 downregulated proteins, specifically CCL28, CCL11, cystatin D, STAM-binding protein, 4E-BP1, matrix metalloproteinase-10, SIRT2, and monocyte chemotactic protein 4, compared with those without (all P < 0.05). The CAD-BSS group had one interleukin-17 (IL-17) upregulated and 10/92 downregulated proteins compared with the CAD-non-BSS group. When compared with the non-CAD-BSS group, the CAD-BSS group had 8 upregulated proteins but only 2 downregulated proteins, namely interleukin-10 receptor subunit alpha (IL-10RA) and TNF-related activation-induced cytokine (both P < 0.05). Totally 10 proteins were identified as potential candidate biomarkers of BSS in CAD patients. After least absolute shrinkage and selection operator regression analysis, two proteins that distinguished between BSS and non-BSS individuals among CAD patients were identified (SIRT2 and 4E-BP1). These proteins are primarily associated with the mechanistic target of rapamycin signaling pathway, which regulates inflammation and oxidative stress.

CONCLUSIONS: Results suggest that the inflammatory response and mechanistic target of rapamycin signaling pathway participate in CAD and BSS development, and that SIRT2 and 4E-BP1 are prospective protein biomarkers for patients with CAD and BSS.

Key words： coronary artery disease; inflammation; blood stasis syndrome; hepatocyte growth factor, sirtuin 2; eukaryotic translation initiation factor 4E-binding protein 1; Olink platform

Cite this article

LI Hongzheng , LIN Guosheng , PENG Yuxuan , Churov Alexey Viktorovich , YANG Wenwen , WANG Jie , LU Jieming , LIAO Feifei , YU Ruotong , WEI Yue , ZHAO Zhiru , LU Aimei , LI Peng , SHEN Aling , LONG Linzi , QU Hua , FU Changgeng . Candidate biomarker identification for blood stasis syndrome among coronary artery disease patients using the Olink proteomics platform[J]. Journal of Traditional Chinese Medicine, 2026 , 46(2) : 490 -500 . DOI: 10.19852/j.cnki.jtcm.2026.02.020

References

1. Konishi T, Virmani R, Jinnouchi H, et al. Plaque histological characteristics in individuals with sudden coronary death. Vascul Pharmacol 2023; 153: 107240.
2. Yazdani AN, Pletsch M, Chorbajian A, Zitser D, Rai V, Agrawal DK. Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease. Expert Rev Cardiovasc Ther 2023; 21: 675-92.
3. Qiu Y, Xu H. Formulation and interpretation of international diagnostic guidelines for blood-stasis syndrome. Chin J Integr Med 2022; 28: 291-6.
4. Ma CY, Liu JH, Liu JX, et al. Relationship between two blood stasis syndromes and inflammatory factors in patients with acute coronary syndrome. Chin J Integr Med 2017; 23: 845-9.
5. Li Y, Sun MQ, Li L, Zhang YH, Miao L, Liu JX. Application and prospect of platelet multi-omics technology in study of blood stasis syndrome. Chin J Integr Med 2022; 28: 99-105.
6. Song M, Wang Y, Annex BH, Popel AS. Experiment-based computational model predicts that IL-6 classic and trans-signaling exhibit similar potency in inducing downstream signaling in endothelial cells. NPJ Syst Biol Appl 2023; 9: 45.
7. Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet 2023; 401: 1293-301.
8. Cardiovascular Professional Committee of the World Federation of Chinese Medicine Societies. International diagnostic guidelines for blood-stasis syndrome. Chin J Integr Med 2022; 28: 297-303.
9. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143: e35-71.
10. Carlyle BC, Kitchen RR, Mattingly Z, et al. Technical performance evaluation of Olink proximity extension assay for blood-based biomarker discovery in longitudinal studies of Alzheimer's disease. Front Neurol 2022; 13: 889647.
11. Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 2014; 9: e95192.
12. Bardou P, Mariette J, Escudié F, Djemiel C, Klopp C. Jvenn: an interactive Venn diagram viewer. BMC Bioinformatics 2014; 15: 293.
13. Glickman JW, Dubin C, Renert-Yuval Y, et al. Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. J Am Acad Dermatol 2021; 84: 370-80.
14. Józefczuk E, Guzik TJ, Siedlinski M. Novel biomarkers and emerging tools to identify causal molecular pathways in hypertension and associated cardiovascular diseases. Kardiol Pol 2023; 81: 221-31.
15. Lind L, ?rnl?v J, Lindahl B, Siegbahn A, Sundstr?m J, Ingelsson E. Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. Atherosclerosis 2015; 242: 205-10.
16. Liu J, Chen B, Lu H, Chen Q, Li JC. Identification of novel candidate biomarkers for acute myocardial infarction by the Olink proteomics platform. Clin Chim Acta 2023; 548: 117506.
17. Ponce-de-Leon M, Linseisen J, Peters A, et al. Novel associations between inflammation-related proteins and adiposity: a targeted proteomics approach across four population-based studies. Transl Res 2022; 242: 93-104.
18. Benes J, Kroupova K, Kotrc M, et al. FGF-23 is a biomarker of RV dysfunction and congestion in patients with HFrEF. Sci Rep 2023; 13: 16004.
19. Schmitz T, Wein B, Heier M, Peters A, Meisinger C, Linseisen J. Baseline fibroblast growth factor 23 is associated with long-term mortality in ST-elevation myocardial infarction-results from the Augsburg myocardial infarction registry. Front Cardiovasc Med 2023; 10: 1173281.
20. Ueland G?, Methlie P, Heie A, et al. Substantial changes in inflammatory and cardiovascular biomarkers in patients with autonomous cortisol secretion. Eur J Endocrinol 2023; 189: 78-86.
21. Song X, Wang H, Wang C, et al. Association of sirtuin gene polymorphisms with susceptibility to coronary artery disease in a North Chinese Population. Biomed Res Int 2022; 2022: 4294008.
22. Yang W, Gao F, Zhang P, et al. Functional genetic variants within the SIRT2 gene promoter in acute myocardial infarction. PLoS One 2017; 12: e0176245.
23. Demirci S, Do?an A, Apdik H, et al. Cytoglobin inhibits migration through PI3K/AKT/mTOR pathway in fibroblast cells. Mol Cell Biochem 2018; 437: 133-42.
24. Tait-Mulder J, Hodge K, Sumpton D, Zanivan S, Vazquez A. The conversion of formate into purines stimulates mTORC1 leading to CAD-dependent activation of pyrimidine synthesis. Cancer Metab 2020; 8:20.
25. Xin QQ, Chen X, Yuan R, et al. Correlation of platelet and coagulation function with blood stasis syndrome in coronary heart disease: a systematic review and Meta-analysis. Chin J Integr Med 2021; 27: 858-66.
26. Wu G, Zhao J, Zhao J, et al. Exploring biological basis of Syndrome diffeentiation in coronary heart disease patients with two distinct Syndromes by integrated multi-omics and network pharmacology strategy. Chin Med 2021; 16: 109.
27. Wang ZB, LI Y, Wang DP, et al. Proteomics analysis of coronary atherosclerotic heart disease with different Traditional Chinese Medicine syndrome types before and after percutaneous coronary intervention. J Tradit Chin Med 2024; 44: 554-63.
28. Wang J, Liu L, Liu C, et al. Identification and analysis of differential miRNA-mRNA interactions in coronary heart disease: an experimental screening approach. Front Cardiovasc Med 2023; 10: 1186297.
29. Mendes KL, Lelis DF, Santos SHS. Nuclear sirtuins and inflammatory signaling pathways. Cytokine Growth Factor Rev 2017; 38: 98-105.
30. Zhang W, Liu D, Ren J, Zhou P, Han X. Overexpression of Sirtuin2 prevents high glucose-induced vascular endothelial cell injury by regulating the p53 and NF-κB signaling pathways. Biotechnol Lett 2018; 40: 271-8.
31. Guo J, Zhang H, Hu H, et al. Silent information regulator 2 deficiency exacerbates chronic cold exposure-induced colonic injury and p65 activation in mice. Gene 2024; 907: 148276.
32. Liu QQ, Ren K, Liu SH, Li WM, Huang CJ, Yang XH. MicroRNA-140-5p aggravates hypertension and oxidative stress of atherosclerosis via targeting Nrf2 and Sirt2. Int J Mol Med 2019; 43: 839-49.
33. Lum MA, Jonas KA, Parmar S, et al. Small-molecule modulators of B56-PP2A restore 4E-BP function to suppress eIF4E-dependent translation in cancer cells. J Clin Invest 2025; 135: e176093.
34. Suginohara T, Wakabayashi K, Ato S, Ogasawara R. Effect of 2-deoxyglucose-mediated inhibition of glycolysis on the regulation of mTOR signaling and protein synthesis before and after high-intensity muscle contraction. Metabolism 2021; 114: 154419.
35. Chen T, Li T, Wang J. p 53 mediates PEDF-induced autophagy in human umbilical vein endothelial cells through sestrin2 signaling. Mol Med Rep 2019; 20: 1443-50.
36. B?hm R, Imseng S, Jakob RP, Hall MN, Maier T, Hiller S. The dynamic mechanism of 4E-BP1 recognition and phosphorylation by mTORC1. Mol Cell 2021; 81: 2403-16.
37. Pi S, Mao L, Chen J, et al. The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting autophagy in advanced atherosclerosis. Autophagy 2021; 17: 980-1000.
38. Cao Y, Liu X, Lu W, et al. Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer. Cancer Lett 2015; 360:141-50.
39. Jeong YJ, Choi Y, Shin JM, et al. Melittin suppresses EGF-induced cell motility and invasion by inhibiting PI3K/Akt/mTOR signaling pathway in breast cancer cells. Food Chem Toxicol 2014; 68: 218-25.
40. Han Z, Yan G, Jousma J, et al. Translational regulation of SND1 governs endothelial homeostasis during stress. J Clin Invest 2025; 135: e168730.
41. Zhao YM, Zhang YL, Wang GZ, et al. Network pharmacology-based analysis of the antithrombotic clinical efficacy and antithrombotic mechanism of Huoxue Jiedu prescription in the treatment of polycythemia vera with heat toxin and blood stasis syndrome. J Tradit Chin Med 2025; 45: 1353-65.
Options
Outlines

/

〈 〉